Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediVector has secured $138.5m contract from the Department of Defense's (DOD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) to further develop Favipiravir (T-705), that targets multiple influenza virus strains.
Subscribe to our email newsletter
JPM-TMT joint project manager David Hough said the drug showed that it can mitigate flu symptoms by interfering with the influenza replication process.
In earlier animal studies and Phase 1 human clinical trials, Favipiravir has shown positive results.
The Phase 3 clinical studies of Favipiravir drug is expected to commence as early as fall 2012.
JPM-TMT facilitates the advanced development and acquisition of broad-spectrum medical countermeasures and systems to improve biodefense response capability.